Zhang 2018a.

Methods	Study design: Randomised clinical trial Study duration: January 2014 to January 2017 Duration of follow‐up: 2 months Setting: Hospital
Participants	Age (mean ± SD): TACE + RFA: 58.62 ± 4.19 years; TACE alone: 57.21 ± 3.98 years Male (n/total): TACE + RFA: 30/48; TACE alone: 29/48 Tumour diameter (mean ± SD, range): TACE + RFA: 6.32 ± 1.24 cm, 5‐15 cm ; TACE: 6.25 ± 1.19 cm, 4‐14 cm
Interventions	TACE + RFA group (n = 48): TACE: Chemotherapeutic drugs: cisplatin 80 mg, theprubicin 30 mg, and epirubicin 20 mg RFA: The interval between TACE and RFA was 2 weeks. RADION‐ICS ablation system. Output power of 40 W, 5‐10 minutes per RFA session. Multiple sessions of RFA were performed, with an interval of 1‐2 weeks. TACE group (n = 48): Chemotherapeutic drugs: cisplatin 80 mg, theprubicin 30 mg, and epirubicin 20 mg
Outcomes	Tumour response, according to WHO criteria Liver function Immune function
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.